A Sacrococcygeal Teratoma (SCT) is a rare medical miracle that occurs in newborn babies, usually in the first month of life. It is an abnormal growth that develops in the area of the baby’s tailbone. It is most often benign, meaning it is non-cancerous, but can also be malignant, or cancerous. In either case, it is a medical emergency that requires immediate attention. SCTs are classified as either type 1 or type 2. Type 1 SCTs are typically benign and occur in the lower portion of the tailbone. Type 2 SCTs are more likely to be malignant and occur higher up in the tailbone. Both types can cause serious health problems for the baby, including breathing difficulties, developmental delays, and even death.
The exact cause of SCT is unknown, but it is believed to be related to genetic factors. It is also thought that environmental factors, such as exposure to certain chemicals or radiation, may play a role.
SCTs are diagnosed through a physical exam and imaging tests such as ultrasound or magnetic resonance imaging (MRI). Treatment depends on the size and type of the tumor, as well as the age and overall health of the baby. For type 1 SCTs, the tumor is usually surgically removed. In some cases, chemotherapy or radiation may be used to shrink the tumor before surgery. For type 2 SCTs, the tumor may be treated with chemotherapy or radiation, or the entire tumor may be surgically removed.
The outlook for babies with SCTs is generally good. With prompt diagnosis and treatment, most babies make a full recovery. However, there is a risk of complications, including infection, bleeding, and organ damage. In some cases, the tumor may recur or spread to other parts of the body.
A Sacrococcygeal Teratoma is a rare medical miracle that can occur in newborn babies. It is classified as either type 1 or type 2, with type 1 being the more common and benign form. Diagnosis and treatment depend on the size and type of the tumor, as well as the age and overall health of the baby. With prompt diagnosis and treatment, most babies make a full recovery, although there is a risk of complications.
1.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Hereditary cancer has a rare and underreported cause.
4.
New imaging guidelines for head and neck cancers, a step toward practice change
5.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
1.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
Essential Updates in Hematology in Daily Practice
4.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
5.
Importance of Early Detection in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
A New Era in Managing Cancer-Associated Thrombosis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation